


# ACIP COVID-19 Vaccines Work Group

**Dr. Beth Bell, Work Group Chair**

**July 29, 2020**



For more information: [www.cdc.gov/COVID19](https://www.cdc.gov/COVID19)

# Background

- Over 200 COVID-19 vaccines currently under development, including three in clinical trials in the United States.
- ACIP responding to ongoing pandemic and accelerated vaccine development through scheduling of monthly emergency ACIP meetings
- At the June 24th meeting, ACIP reviewed:
  - Overview of the COVID-19 Vaccine Work Group and terms of reference
  - SARS-CoV-2 disease, immunology, and epidemiology
  - COVID-19 vaccine development and the vaccine landscape
  - COVID-19 vaccine prioritization considerations

# COVID-19 Work Group activities – July, 2020

- COVID-19 Vaccine Work Group meets weekly
- Topics covered in July:
  - Review of published phase I clinical trial results
  - Safety considerations for COVID-19 vaccines
  - Regulatory mechanisms for the deployment of COVID-19 vaccines
  - Epidemiology updates, including COVID-19 in healthcare personnel
  - COVID-19 vaccine prioritization considerations
  - Evidence to Recommendations framework to guide COVID-19 vaccine policy

# Today's agenda

- **Overview of COVID-19 vaccine clinical trials:** Dr. Julie Ledgerwood (NIAID)
- **COVID-19 vaccine safety considerations:** Dr. Kathryn Edwards (Vanderbilt University)
- **Considerations for FDA licensure vs. Emergency Use Authorization of COVID-19 vaccines:** Dr. Doran Fink (FDA)
- **Considerations for vaccine implementation:** Dr. Nancy Messonnier (CDC)
- **Epidemiology of COVID-19 in essential workers, including healthcare personnel:** Dr. Sara Oliver (CDC)
- **COVID-19 vaccine prioritization: work group considerations:** Dr. Sarah Mbaeyi (CDC)
- **Evidence to Recommendations framework and Work Group next steps:** Dr. Kathleen Dooling (CDC)

# Considerations for prioritization of COVID-19 vaccines

- Work Group reviewing considerations for vaccine prioritization in specific groups using a phased approach:
  - Essential workers, including healthcare personnel
  - Persons at increased risk for severe COVID-19 disease (e.g., older adults, persons with underlying conditions, racial/ethnic minority groups)
  - General population
- Today's session: Focus on essential workers, including healthcare personnel
- Review of prioritization considerations for other groups will be reviewed at upcoming ACIP meetings

# National Academies of Science Engineering and Medicine

## Committee on Equitable Allocation of Vaccine for the Novel Coronavirus

*“...a committee that will develop an overarching framework to assist policymakers in the U.S. and global health communities in planning for equitable allocation of vaccines against COVID-19”*

Committee co-sponsored by NIH and CDC to inform the decisions by health authorities, including the ACIP:

- What criteria should be used in setting priorities for equitable allocation of vaccine?
- How should the criteria be applied in determining the first tier of vaccine recipients?
- How can countries ensure equity in allocation of COVID-19 vaccines?
- For the US, how can communities of color be assured access to vaccination?
- What steps should be taken to mitigate vaccine hesitancy, especially among high-priority populations?

# Work group members

## ACIP members

- Beth Bell (chair)
- Grace Lee
- Jose Romero
- Keipp Talbot

## Ex-officio/government members

- FDA: Doran Fink, Rachel Zhang
- NIH: Chris Roberts
- IHS: Thomas Weiser, Jillian Doss-Walker
- DOD: Eric Deussing
- CMS: Jeff Kelman
- BARDA: Christine Oshansky

## CDC Co-leads

- Kathleen Dooling
- Sarah Mbaeyi

## Liaisons

- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett
- IDSA: Jeff Duchin (primary), Carol Baker (alternate)

## Liaisons, cont’d

- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis (primary), Althea House (alternate)
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Oliver Brooks
- SHEA: Marci Drees


## Consultants

- Ed Belongia (safety)
- Matthew Daley (safety)
- Kathy Kinlaw (ethics)
- Dayna Matthew (health equity)
- Kathleen Neuzil (vaccinology)
- Stanley Perlman (microbiology/immunology)

# CDC participants

- Doug Campos-Outcalt
- Thomas Clark
- Amanda Cohn
- Jean Cox-Ganser
- Jonathan Duffy
- Anthony Fiore
- Mark Freedman
- Sue Gerber
- Jack Gersten
- Sam Graitcer
- Lisa Grohskopf
- Rita Helfand
- Terri Hyde
- Tara Jatlaoui
- Cynthia Jorgensen
- Jessica MacNeil
- Rebecca Morgan
- Sara Oliver
- Anita Patel
- Stephanie Schrag
- Tom Shimabukuro
- Nathalie Thornburg
- Jennifer Verani
- Cindy Weinbaum
- Yon Yu
- Jane Zucker





For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

# Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

